FDA 21 CFR Part 11 &amp; E-Signature Compliance Guides

EU GMP Annex 11 2025 Draft: Electronic Signature Changes and MFA Requirement

The EMA's 2025 consultation draft of EU GMP Annex 11 makes multi-factor authentication explicitly mandatory for electronic signatures in GxP systems — the most significant update since the 2011 publication. Updated June 2026: comment period closed October 2025 and finalization is approaching mid-year. Covers Clause 12.1 MFA requirement, Clause 9 expanded audit trail scope, Clause 16 AI attribution, how the draft compares to FDA Part 11 Section 11.200(a), and preparation steps for the finalization window.

May 23, 202612 min read

GxP Electronic Records: What FDA, EMA, and ICH Regulations Actually Require in 2026

GxP compliance means four different regulatory frameworks with different text and different enforcement bodies. This guide cites the actual regulatory text — FDA 21 CFR Part 11 Section 11.10(e), EU GMP Annex 11 (2025 draft) Clause 12.1, and ICH E6(R3) Section 5.5.3 — showing exactly what each requires for electronic records, audit trails, and electronic signatures. Includes a 7-question vendor evaluation table testing claims against the regulatory text.

May 20, 202614 min read

Electronic Signatures for Clinical Trials: Site Coordinator, Sponsor, and CRO Responsibilities

Electronic signatures in clinical trials are a shared obligation across three regulated parties. This guide breaks down the specific Part 11 responsibilities of sponsors, CROs, and investigator sites under the FDA's October 2024 final guidance, covering vendor qualification, non-repudiation letters, delegation of authority logs, authentication at signing, and the documents most likely to fail at each level. Updated June 2026 with ESG NextGen portal submission change for non-repudiation letters.

May 18, 202614 min read

GxP Compliant Electronic Signatures: What the Regulations Require and How to Select a Platform

GxP compliant electronic signatures must satisfy FDA 21 CFR Part 11 as a foundation, then layer on discipline-specific requirements from GMP, GLP, and GCP. This guide explains what each regulation actually requires, how the February 2026 QMSR implementation changed the GMP picture for medical devices, what EU GMP Annex 11 adds for multi-regional organizations, and a 10-question technical checklist for evaluating whether a platform is genuinely GxP compliant versus simply claiming it.

May 17, 202613 min read

HIPAA and 21 CFR Part 11: Dual Compliance for Healthcare Research

Healthcare research sites face simultaneous obligations under HIPAA and 21 CFR Part 11. Updated May 2026 to cover the March 2026 CMS final rule establishing the first HIPAA-adopted standard for electronic signatures in claims attachments — and what it means for organizations that must satisfy both federal frameworks at once. Covers the BAA requirement, two-component authentication at signing, signature meaning, non-repudiation letter obligations, and dual-compliance vendor selection.

May 11, 202612 min read

21 CFR Part 11 for Small Clinical Research Sites: What Site Coordinators Need to Know

Small investigator sites face the same FDA 21 CFR Part 11 obligations as large sponsors — but with fewer resources. This practical guide covers the six document types that require compliant e-signatures at research sites, what sponsors check during site qualification, the non-repudiation letter requirement, and a three-SOP framework for sites without a dedicated QA team.

May 9, 202611 min read

FDA Part 11 Non-Repudiation Letter: What It Is, How to Write It, and Where to Submit

Under 21 CFR 11.100(c), any organization using electronic signatures in FDA-regulated activities must certify in writing to FDA that those signatures are legally binding. Updated May 2026: the FDA ESG NextGen Unified Submission Portal now requires electronic upload of non-repudiation agreements during account registration — physical mailing is no longer required for new ESG accounts. This guide covers who must submit, what the letter must say, the new portal process, whether one letter covers all studies, and what CROs need to know.

May 6, 202611 min read

ALCOA++ Data Integrity: Understanding the Tenth Principle for Pharmaceutical Audit Trails

ALCOA++ adds a tenth data integrity principle — Traceable — to the familiar ALCOA+ framework. This guide covers what Traceable requires for pharmaceutical audit trail software, the EU GMP Chapter 4 ALCOA++ codification approaching finalization, the EMA-PIC/S joint consultation on data integrity alignment, and what multi-regional organizations must do to satisfy both FDA and EU requirements simultaneously. Updated June 2026: EU GMP Annex 11 Clause 9 audit trail lifecycle expansion now approaching enforcement window.

May 4, 202612 min read

Electronic Signature SOPs: What FDA Part 11 Requires and How to Write Them

FDA 21 CFR Part 11 Section 11.10(j) explicitly requires written policies holding individuals accountable for their electronic signatures. This guide covers the six SOPs every Part 11 system needs, what FDA investigators check during SOP audits, and how to structure each procedure.

May 3, 202613 min read

April 27, 202612 min read

21 CFR Part 11 Electronic Signature Validation: IQ OQ PQ Step-by-Step Guide

A practical guide to IQ, OQ, and PQ validation for 21 CFR Part 11 e-signature systems, including CSA's risk-based approach, specific test cases for each Part 11 control, and what FDA investigators look for.

April 20, 202612 min read

Electronic Signatures for CROs: What Contract Research Organizations Need for Part 11 Compliance

CROs are explicitly named as regulated entities in the October 2024 FDA guidance, with Part 11 obligations enforceable through the sponsor-CRO written agreement. This guide covers the non-repudiation letter requirement, dual-site accountability, TMF e-signature requirements for CRO monitoring workflows, delegation of authority log management across multi-site environments, and system qualification responsibility.

April 13, 202613 min read

Clinical Trial Document Management: E-Signature Requirements for Sites and Sponsors

Managing clinical trial documents with e-signatures requires a framework that satisfies FDA 21 CFR Part 11, ICH E6(R3), and the October 2024 FDA final guidance. This guide covers the documents sites and sponsors must sign, delegation of authority log requirements, TMF retention obligations, and platform evaluation criteria.

April 10, 202615 min read

What Makes an E-Signature Platform FDA Compliant? The Complete Technical Checklist

Every e-signature vendor claims FDA compliance. This guide explains what Part 11 Subpart B and Subpart C actually require at the technical level — hash-chained audit trails, authentication at signing, signature meaning, tamper-evident records, and validation documentation — plus a 14-question checklist to run against any vendor.

April 10, 202614 min read

E-Signatures for Pharmaceutical QA: Batch Records, SOPs, and Deviation Reports

Pharmaceutical QA signatures on batch records, SOPs, deviations, and CAPA reports must meet FDA 21 CFR Part 11 and Part 211 requirements. This guide covers GMP-specific signature obligations including reason-for-change, batch record audit trail review, SOP routing enforcement, and the critical differences between general e-signature tools and purpose-built GMP platforms.

GxP Electronic Signature Requirements: What GMP, GLP, and GCP Each Demand

GMP, GLP, and GCP all require FDA 21 CFR Part 11 compliance for electronic signatures, but each discipline adds specific obligations on top of the shared foundation. This guide compares what each GxP discipline requires — from GCP non-repudiation letters and delegation of authority logs to GLP study director designations and GMP per-batch audit trail reviews.

April 7, 202614 min read

21 CFR Part 11 Compliant Electronic Records: Subpart B Requirements Explained

Subpart B of FDA 21 CFR Part 11 defines the requirements for compliant electronic records, covering validation, audit trails, access controls, record retention, and signature-to-record linking. This guide explains each section of Subpart B, common FDA 483 failures, and what the 2024 clinical investigations guidance changed for cloud-based systems.

April 6, 202612 min read

FDA Inspection Readiness: Audit Trail Requirements and the Pre-Inspection Checklist (2026)

What does an FDA investigator actually request when reviewing electronic signature audit trails? This guide covers what investigators ask for, the 5 most common 483 audit trail findings, the April 2026 one-day inspection pilot and same-day readiness requirements, 2026 SOP enforcement trends, and a 10-item pre-inspection checklist specific to e-signature audit trails. Not EDC platform readiness — this is the guide for your electronic signature audit trail. Updated June 2026.

April 4, 202613 min read

March 30, 202611 min read

Choosing the Best E-Signature for Clinical Trials: 8 Requirements

What makes an e-signature platform right for clinical trials? This guide covers the 8 specific requirements drawn from 21 CFR Part 11, the FDA's 2024 final guidance, ICH E6(R3), and EU CTR 536/2014 — including guest signing, delegation of authority logs, IQ/OQ validation docs, and 25-year retention.

March 30, 202612 min read

Electronic Signature Audit Trail Requirements: 21 CFR Part 11, Annex 11, and ALCOA+

What does FDA actually require for electronic signature audit trails? This guide covers the specific requirements under 21 CFR Part 11 Section 11.10(e), EU GMP Annex 11 Clause 9, and ALCOA+ — including what inspectors look for and the most common audit trail failures in FDA 483 observations.

March 27, 202611 min read

ALCOA+ Audit Trail Software Requirements: Complete Life Sciences Guide (2026)

What does ALCOA+ compliant audit trail software actually need to do? This guide covers the 8 core technical requirements, the ALCOA++ Traceable principle, EU GMP Chapter 4 ALCOA++ codification nearing finalization, the EMA-PIC/S joint consultation on data integrity, and 2026 FDA inspection enforcement trends showing audit trail findings in over 30% of regulated software inspections. Updated June 2026: EU GMP Annex 11 finalization approaching mid-year — Clause 9 audit trail scope expansion now the primary gap to assess.

March 27, 202612 min read

Best 21 CFR Part 11 Compliant E-Signature Software (2026): What Actually Matters

Most vendors claim Part 11 compliance. Few can back it up technically. This guide covers the 7 requirements that separate genuinely compliant e-signature platforms from those that just claim it, plus vendor evaluation questions, CSA first-year implementation patterns, the April 2026 one-day inspection pilot, FDA ESG NextGen portal change, and how the EU GMP Annex 11 2025 draft Clause 12.1 MFA requirement raises the authentication bar as finalization approaches mid-2026.

Part 11 Electronic Signatures: Requirements, Components, and Common Mistakes

A practical guide to 21 CFR Part 11 electronic signature requirements -- Subpart B and Subpart C explained, common compliance failures at clinical research sites, and what FDA inspectors look for in 2026.

March 23, 20269 min read

Data Privacy

Electronic Signatures and GDPR Compliance: Full Guide

E-signature workflows process personal data (names, emails, IPs) subject to GDPR. This guide covers lawful bases under Article 6, data minimization, DPA requirements, cross-border transfers, data subject rights, retention policies, and a 12-point compliance checklist.

March 16, 20269 min read

FDA Warning Letters Are Up 73%. Is Your Audit Trail Ready?

FDA warning letters jumped 73% in H2 2025. Here's what clinical trial sponsors and CROs need to know about Part 11 audit trails before your next inspection.

March 16, 20268 min read

March 14, 202610 min read

ALCOA+ Data Integrity: 9 Principles for Life Sciences

ALCOA+ stands for Attributable, Legible, Contemporaneous, Original, Accurate, Complete, Consistent, Enduring, and Available. This guide explains each principle with GxP examples, common FDA 483 violations, and practical implementation strategies for electronic records.

March 13, 202610 min read

Audit Trails in Regulated Industries: Complete Guide

An audit trail is a secure, computer-generated record of who did what, when, and why in a regulated system. This guide covers FDA 21 CFR Part 11 Section 11.10(e), EU GMP Annex 11, hash chain verification, common 483 findings, and implementation best practices.

March 12, 202611 min read

EU Clinical Trial Regulation 536/2014: Sponsor Guide

EU CTR 536/2014 replaced the Clinical Trials Directive with a harmonized framework featuring the CTIS portal, single application process, and mandatory 25-year retention under Article 58. This guide covers documentation, timelines, transparency, and e-signature requirements.

March 11, 202611 min read

DocuSign Part 11 Module vs Purpose-Built Compliance Platforms

DocuSign addresses FDA 21 CFR Part 11 through a paid add-on module. Purpose-built platforms embed compliance controls natively. This guide compares the two architectures across audit trails, 2FA, validation burden, total cost of ownership, and organizational fit for life sciences.

March 11, 202612 min read

How to Validate an E-Signature System: IQ/OQ/PQ Under CSA

Learn how to validate an e-signature system using IQ/OQ/PQ under FDA's 2025 Computer Software Assurance (CSA) guidance. Covers risk-based testing, Part 11 mapping, qualification checklists, change control, and common validation pitfalls for pharma, biotech, and medical device companies.

March 11, 202616 min read

E-Signature Vendor Evaluation Checklist: RFP Questions for Regulated Life Sciences

40+ RFP questions for evaluating e-signature vendors in pharma, biotech, and CROs. Covers FDA 21 CFR Part 11, EU GMP Annex 11, and ALCOA+ data integrity requirements with a weighted scoring template.

FDA Warning Letters & Data Integrity: Lessons from Real Enforcement Actions

Data integrity deficiencies appear in 60-80% of FDA drug GMP warning letters. This guide examines real warning letters citing shared logins, missing audit trails, backdated records, and absent training — with consequences including consent decrees, import bans, and criminal prosecution.

March 11, 202611 min read

Decentralized Clinical Trials & eConsent: E-Signature Requirements

Decentralized clinical trials (DCTs) use telehealth and direct-to-patient technologies for remote trial conduct. This guide covers the FDA's September 2024 DCT guidance, eConsent best practices, e-signature compliance under Part 11 and ICH E6(R3), and data integrity for remote workflows.

March 11, 202612 min read

How to Migrate to a Part 11 E-Signature Platform: 6-Phase Framework

Migrating from paper or legacy systems to a 21 CFR Part 11 compliant e-signature platform requires structured change control. This guide covers a six-phase migration framework: requirements, validation, pilot, parallel running, cutover, and decommission — with audit trail continuity and training strategies.

Medical Device E-Signatures Under QMSR, ISO 13485 & EU MDR

The FDA's QMSR replaced the QSR on February 2, 2026, incorporating ISO 13485:2016 by reference. This guide covers how e-signatures interact with the new QMSR, Part 11's independent requirements, EU MDR documentation obligations, and validation strategies for dual-market medical device companies.

AI & Electronic Signatures in Regulated Industries: Compliance Guide

AI is transforming e-signature workflows in life sciences — from intelligent document routing to anomaly detection and predictive compliance. This guide covers the FDA's AI guidance, EU AI Act high-risk classification, Part 11 implications, and a risk-based framework for adopting AI-enhanced compliance tools.

CSV vs CSA: Computer System Validation vs Software Assurance Explained

FDA's Computer Software Assurance (CSA) guidance, finalized September 2025, replaces traditional CSV with risk-based validation. This guide compares CSV and CSA approaches, explains risk classification for e-signature functions, and provides practical transition strategies for life sciences organizations.

EU GMP Annex 11 (2025 Draft): Computerized Systems Compliance Guide

The 2025 draft revision of EU GMP Annex 11 expands from 5 to 19 pages, adding provisions for AI, cybersecurity, cloud/SaaS, and enhanced e-signature requirements including multi-factor authentication and eIDAS alignment. Updated June 2026: the EMA comment period closed October 2025 and finalization is expected mid-2026. Covers key changes, FDA Part 11 comparison, and preparation strategies for the finalization window now approaching.

March 10, 202611 min read

How to Choose an E-Signature Platform for Life Sciences

Evaluating e-signature platforms for pharma, biotech, and medical devices? This guide covers FDA 21 CFR Part 11 compliance, audit trail capabilities, 2FA requirements, validation documentation, red flags to avoid, and total cost of ownership for regulated industries.

Healthcare

HIPAA-Compliant Electronic Signatures: Requirements Guide

HIPAA allows electronic signatures but requires BAAs, encryption (AES-256), audit controls, and MFA for documents containing PHI. This guide covers Security Rule safeguards, BAA requirements, audit trails, and best practices for healthcare organizations.

March 6, 20269 min read

eIDAS vs ESIGN Act: Complete Comparison Guide (2026)

The EU eIDAS Regulation defines three signature tiers (SES, AES, QES) while the US ESIGN Act is technology-neutral with a single tier. This guide compares legal frameworks, cross-border recognition, eIDAS 2.0 changes, and compliance strategies for multinational organizations.

March 3, 20269 min read

February 28, 202610 min read

GxP Compliance for Electronic Records: GLP, GMP, GCP Guide

GxP compliance requires electronic records to be attributable, immutable, and audit-trailed. This guide covers GLP, GMP, GCP, GDP, and GVP requirements, ALCOA+ principles, EU Annex 11, system validation (IQ/OQ/PQ), and best practices for life sciences. Updated May 2026 with QMSR implementation and EU GMP Annex 11 draft revision status.

February 25, 202614 min read

Electronic Signatures in Clinical Trials: 2024 FDA Guidance Update

The FDA finalized 29 Q&As on electronic systems in clinical investigations in October 2024, resolving ambiguities around non-repudiation letters, hybrid records, cloud platforms, and risk-based validation. This guide explains what changed and what it means for sponsors, CROs, and research sites. Updated June 2026 with ICH E6(R3) final implementation status, FDA ESG NextGen portal update, and EU GMP Annex 11 2025 draft MFA implications for EU trial sites.